Head-to-head evidence
HRC0202 vs Pamlectabart tismanitin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
HRC0202
Developed by Hrain Biotechnology Co., Ltd.
NCT04003168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published report covers seven treated patients, fewer than the study's listed enrollment.
Pamlectabart tismanitin
Developed by Heidelberg Pharma AG
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT04879043 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRC0202's landscape · Pamlectabart tismanitin's landscape